We are live on
!
Find out more
ETC
Exchange Traded Concepts Portfolio holdings
AUM
$21.9B
1-Year Est. Return
68.6%
This Fund
S&P 500
This Quarter
Est. Return
+7.15%
1 Year Est. Return
+68.6%
3 Year Est. Return
+158.93%
5 Year Est. Return
+186.62%
10 Year Est. Return
–
AUM
$4.06B
AUM Growth
+$411M
(+11%)
Cap. Flow
+$205M
Cap. Flow
% of AUM
5.05%
Top 10 Holdings %
Top 10 Hldgs %
21.64%
Holding
1,420
New
288
Increased
397
Reduced
560
Closed
115
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Long-Term Bond ETF
BLV
|
+$159M |
| 2 |
iShares Core US REIT ETF
USRT
|
+$137M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$125M |
| 4 |
Vanguard Extended Market ETF
VXF
|
+$95.4M |
| 5 |
Vanguard Long-Term Treasury ETF
VGLT
|
+$69.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$730M |
| 2 |
Goldman Sachs Access Treasury 0-1 Year ETF
GBIL
|
+$487M |
| 3 |
NVIDIA
NVDA
|
+$30.3M |
| 4 |
Verizon
VZ
|
+$19.7M |
| 5 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$18.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.96% |
| 2 | Energy | 10.24% |
| 3 | Healthcare | 10.11% |
| 4 | Industrials | 5.84% |
| 5 | Consumer Discretionary | 5.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
876
Bicycle Therapeutics
BCYC
$274M
| $135K | ﹤0.01% |
+5,276
| New | +$123K |
|
|
INBX
877
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $134K | ﹤0.01% |
+5,165
| New | +$121K |
|
878
Erasca
ERAS
$6.24B
| $134K | ﹤0.01% |
+48,513
| New | +$138K |
|
|
IPHA
879
Innate Pharma
IPHA
$172M
| $133K | ﹤0.01% |
+42,431
| New | +$130K |
|
880
IDEAYA Biosciences
IDYA
$3.44B
| $133K | ﹤0.01% |
+5,650
| New | +$116K |
|
881
BioNTech
BNTX
$23.1B
| $133K | ﹤0.01% |
+1,230
| New | +$138K |
|
882
Toll Brothers
TOL
$14.5B
| $133K | ﹤0.01% |
1,677
+191
| +13% | +$12.8K |
|
883
DuPont de Nemours
DD
$19.1B
| $132K | ﹤0.01% |
1,475
+1,457
| +8,094% | +$125K |
|
884
ImmunityBio
IBRX
$7.03B
| $132K | ﹤0.01% |
+47,540
| New | +$134K |
|
885
Xencor
XNCR
$1.43B
| $131K | ﹤0.01% |
+5,228
| New | +$142K |
|
|
SWTX
886
DELISTED
SpringWorks Therapeutics
SWTX
| $130K | ﹤0.01% |
+4,972
| New | +$131K |
|
887
Tango Therapeutics
TNGX
$4.15B
| $130K | ﹤0.01% |
+39,158
| New | +$141K |
|
888
ON Semiconductor
ON
$33B
| $128K | ﹤0.01% |
1,355
-1
| -0.1% | -$83 |
|
889
CubeSmart
CUBE
$9.76B
| $128K | ﹤0.01% |
2,868
-1,939
| -40% | -$88K |
|
|
PNT
890
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $128K | ﹤0.01% |
+14,102
| New | +$124K |
|
|
ITOS
891
DELISTED
iTeos Therapeutics
ITOS
| $127K | ﹤0.01% |
+9,624
| New | +$137K |
|
|
IGMS
892
DELISTED
IGM Biosciences
IGMS
| $127K | ﹤0.01% |
+13,800
| New | +$155K |
|
893
MacroGenics
MGNX
$238M
| $126K | ﹤0.01% |
+23,534
| New | +$145K |
|
894
Cullinan Oncology
CGEM
$1.06B
| $125K | ﹤0.01% |
+11,661
| New | +$124K |
|
895
Kymera Therapeutics
KYMR
$8.8B
| $125K | ﹤0.01% |
+5,440
| New | +$156K |
|
896
Xenon Pharmaceuticals
XENE
$6.24B
| $125K | ﹤0.01% |
+3,247
| New | +$129K |
|
|
DAWN
897
DELISTED
Day One Biopharmaceuticals
DAWN
| $124K | ﹤0.01% |
+10,413
| New | +$136K |
|
898
PPG Industries
PPG
$27.2B
| $124K | ﹤0.01% |
837
+826
| +7,509% | +$115K |
|
899
Allogene Therapeutics
ALLO
$570M
| $124K | ﹤0.01% |
+24,937
| New | +$135K |
|
900
Precigen
PGEN
$1.92B
| $124K | ﹤0.01% |
+107,685
| New | +$127K |
|
Similar funds
DSA
IC
AM
BA
AA
MMH
Exchange Traded Concepts's Q2 2023 Portfolio in Review
As of Q2 2023, Exchange Traded Concepts held 1,420 positions worth $4.06B, up 11% from $3.65B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Exchange Traded Concepts deployed $205M of net new capital in Q2 2023, opening 288 new positions and adding to 397 existing holdings. Its largest new stake was Vanguard Long-Term Bond ETF: 2,114,708 shares worth $158M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 22% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was iShares 0-3 Month Treasury Bond ETF, an estimated $730M trimmed.
- Exchange Traded Concepts's largest Q2 2023 buy was Vanguard Long-Term Bond ETF: 2,114,708 shares worth $158M.
- Exchange Traded Concepts added most to Vanguard Long-Term Treasury ETF in Q2 2023, an estimated $69.8M increase.
- Exchange Traded Concepts's biggest Q2 2023 reduction was iShares 0-3 Month Treasury Bond ETF, cutting an estimated $730M.
- Exchange Traded Concepts fully exited Goldman Sachs Access Treasury 0-1 Year ETF in Q2 2023, selling an estimated $487M.
- Exchange Traded Concepts's ten largest holdings make up 22% of its $4.06B portfolio in Q2 2023.
- Exchange Traded Concepts opened 288 new positions and closed 115 in Q2 2023.
- Exchange Traded Concepts's portfolio value rose 11% quarter-over-quarter to $4.06B.
Based on Exchange Traded Concepts's 13F filing for Q2 2023, filed 20 Jul 2023.